Ibrance Tablet, Film Coated
Product Images NDC 0069-0486

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Ibrance (NDC 0069-0486). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pfizer Laboratories Div Pfizer Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Ibrance 01)

Chemical structure of palbociclib, the active ingredient in Ibrance tablets. The diagram shows the molecular arrangement of atoms and bonds characteristic of this compound.*

FDA Label Image

Figure 1 (Ibrance 02)

A Kaplan-Meier curve chart showing progression-free survival probability (%) over time in months for patients treated with palbociclib plus letrozole versus placebo plus letrozole. The chart includes survival curves, a legend, and patient numbers at risk at different time points.*

FDA Label Image

Figure 2 (Ibrance 03)

A Kaplan-Meier survival curve graph showing progression-free survival probability (%) over time in months comparing two groups: palbociclib plus fulvestrant versus placebo plus fulvestrant. The chart includes the number of patients at risk at several time points for each treatment group.*

FDA Label Image

Figure 3 (Ibrance 04)

A Kaplan-Meier survival curve showing overall survival probability (%) over time in months for two groups: palbociclib plus fulvestrant and placebo plus fulvestrant. The graph includes a table below indicating the number of patients at risk at various time points for both groups.*

FDA Label Image

Logo (Ibrance 05)

FDA Label Image

Logo (Ibrance 06)

FDA Label Image

Principal Display Panel (Topper Card)

An Ibrance monthly box treatment cycle tracker diagram showing three weekly packs labeled Week 1, Week 2, and Week 3 containing Ibrance medication, followed by a Week 4 pack labeled as No Ibrance. The tracker includes sections to fill in start dates for Week 1 and the next treatment cycle after Week 4, with fields for month and day.*

FDA Label Image

Principal Display Panel (75 mg Tablet Dose Pack)

Packaging label for Ibrance (palbociclib) tablets, 75 mg per tablet, film-coated oral tablets. The weekly blister pack contains 7 tablets. Label includes dosage instructions indicating one tablet daily for 21 consecutive days followed by 7 days off treatment. Distributed by Pfizer Laboratories Div Pfizer Inc.*

FDA Label Image

Principal Display Panel (75 mg Tablet Dose Pack Carton)

Ibrance (palbociclib) 75 mg film-coated tablets carton label. The monthly box contains 21 tablets packaged as 3 individual weekly packs, each with 7 tablets. Label shows Pfizer as the manufacturer and includes storage instructions and barcode. The carton design features blue and white colors with branding and dosage details prominently displayed.*

FDA Label Image

Principal Display Panel (100 mg Tablet Dose Pack)

Ibrance 100 mg tablets blister pack label from Pfizer Laboratories. The label indicates the dosage form as tablets containing 100 mg of palbociclib, with instructions to take one tablet once daily for 21 consecutive days followed by 7 days off treatment. The packaging shows a weekly blister pack containing 7 tablets, storage information, and Pfizer's logo.*

FDA Label Image

Principal Display Panel (100 mg Tablet Dose Pack Carton)

Packaging label for Ibrance (palbociclib) tablets, 100 mg strength. The label indicates a package size of 21 tablets, divided into 3 weekly packs, each containing 7 tablets. The labeler is Pfizer Laboratories Div Pfizer Inc. The label includes storage instructions and dosage information, with prominent purple and white color scheme.*

FDA Label Image

Principal Display Panel (125 mg Tablet Dose Pack)

Ibrance 125 mg film-coated oral tablets packaging label by Pfizer Laboratories Div Pfizer Inc. The label indicates a weekly pack containing 7 tablets with instructions for taking 1 tablet once daily for 21 consecutive days followed by 7 days off treatment. The label includes storage information and dosage instructions, and displays the proprietary name Ibrance, generic name palbociclib, and strength 125 mg per tablet.*

FDA Label Image

Principal Display Panel (125 mg Tablet Dose Pack Carton)

Packaging label for IBRANCE (palbociclib) tablets, 125 mg, manufactured by Pfizer Laboratories Div Pfizer Inc. The label indicates it contains 21 film-coated tablets organized in 3 individual weekly packs with 7 tablets each. The box includes dosage and storage instructions, a barcode, and regulatory information, with a green and white color scheme.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.